A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk

British Journal of Nutrition

Volumn 115, Issue 2, 2016, Pages 305-314

  Deschasaux, Mélanie ^a   Souberbielle, Jean Claude ^b   Latino Martel, Paule ^a   Sutton, Angela ^c   Charnaux, Nathalie ^c   Druesne Pecollo, Nathalie ^a   Galan, Pilar ^a   Hercberg, Serge ^a,d   Le Clerc, Sigrid ^a   Kesse Guyot, Emmanuelle ^a   Ezzedine, Khaled ^a,e   Touvier, Mathilde ^a  

^a Unité de Recherches Mesures Physiques Métrologie   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d AVICENNE HOSPITAL   (France)

^e HÔPITAL SAINT ANDRÉ   (France)

Author keywords

25 Hydroxyvitamin D; Nested case control studies; Parathyroid hormone; Prostate cancer risk; SNP

Indexed keywords

25 HYDROXYVITAMIN D; PARATHYROID HORMONE; 25-HYDROXYVITAMIN D; CALCITRIOL RECEPTOR; PLACEBO; RETINOID X RECEPTOR; VITAMIN D;

ADULT; CANCER DIAGNOSIS; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW; VITAMIN BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; GENETICS; GENOTYPE; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PLACEBOS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RETINOID X RECEPTORS; RISK FACTORS; VITAMIN D;

EID: 84951560483     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114515004353     Document Type: Review

References (47)

1. Schwartz GG, Whitlatch LW, Chen TC, et al. (1998) Human prostate cells synthesize 1, 25-Dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7, 391-395.
2. Feldman D, Krishnan AV, Swami S, et al. (2014) The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14, 342-357.
3. Swami S, Krishnan AV, Wang JY, et al. (2012) Dietary vitamin D(3) and 1, 25-Dihydroxyvitamin D(3) (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 153, 2576-2587.
4. Rohan JN, & Weigel NL (2009) 1Alpha, 25-Dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology 150, 2046-2054.
5. World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) (2014) Systematic Literature Review-Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer. Washington, DC: AICR.
6. Norman AW (2008) From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 88, 491S-499S.
7. Felsenfeld AJ, Rodriguez M, & Aguilera-Tejero E (2007) Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol 2, 1283-1305.
8. DeLuca HF (2004) Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80, 1689S-1696S.
9. Brandstedt J, Almquist M, Manjer J, et al. (2012) Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study. Cancer Causes Control 23, 1377-1385.
10. Xu Y, He B, Pan Y, et al. (2014) Systematic review and meta-Analysis on vitamin D receptor polymorphisms and cancer risk. Tumour Biol 35, 4153-4169.
11. Guo Z, Wen J, Kan Q, et al. (2013) Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-Analysis involving 21756 subjects. Tumour Biol 34, 3189-3200.
12. Yin M, Wei S, & Wei Q (2009) Vitamin D receptor genetic polymorphisms and prostate cancer risk: a meta-Analysis of 36 published studies. Int J Clin Exp Med 2, 159-175.
13. Gilbert R, Bonilla C, Metcalfe C, et al. (2015) Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1, 25-Dihydroxyvitamin-D, and prostate cancer: a nested case-control study. Cancer Causes Control 26, 205-218.
14. Mondul AM, Shui IM, Yu K, et al. (2013) Genetic variation in the vitamin d pathway in relation to risk of prostate cancer-results from the breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev 22, 688-696.
15. Shui IM, Mucci LA, Wilson KM, et al. (2013) Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. Cancer Epidemiol Biomarkers Prev 22, 118-126.
16. Holt SK, Kwon EM, Koopmeiners JS, et al. (2010) Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 70, 1448-1460.
17. Hercberg S, Preziosi P, Briancon S, et al. (1998) A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study-design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants. Control Clin Trials 19, 336-351.
18. World Health Organization (2010) ICD-10, International Classification of Diseases and Related Health Problems, 10th rev. ed. Geneva: WHO.
19. Le Moullec N, Deheeger M, Preziosi P, et al. (1996) Validation du manuel photo utilise pour l'enquête alimentaire de l'etude SU.VI.MAX (Validation of the food portion size booklet used in the SU.VI.MAX study). Cah Nutr Diet 31, 158-164.
20. Hercberg S (2005) Table de composition SU.VI.MAX des aliments (SU.VI.MAX Food Composition Table). Paris: Les editions INSERM/Economica.
21. Touvier M, Deschasaux M, Montourcy M, et al. (2015) Determinants of vitamin D status in Caucasian adults: influence of sun exposure, dietary intake, socio-Demographic, lifestyle, anthropometric and genetic factors. J Invest Dermatol 135, 378-388.
22. Touvier M, Deschasaux M, Montourcy M, et al. (2014) Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 99, 1196-1203.
23. Knudsen CS, Nexo E, Hojskov CS, et al. (2012) Analytical validation of the Roche 25-OH Vitamin D total assay. Clin Chem Lab Med 50, 1965-1968.
24. Rakel A, Brossard JH, Patenaude JV, et al. (2005) Overproduction of an amino-Terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol (Oxf) 62, 721-727.
25. Willett WC, Howe GR, & Kushi LH (1997) Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 65, 1220S-1228S.
26. Institute of Medicine (2011) Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press.
27. Xu Y, Shao X, Yao Y, et al. (2014) Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-Analysis. J Cancer Res Clin Oncol 140, 1465-1477.
28. Tuohimaa P, Tenkanen L, Ahonen M, et al. (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108, 104-108.
29. Kristal AR, Till C, Song X, et al. (2014) Plasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 23, 1494-1504.
30. Meyer HE, Robsahm TE, Bjorge T, et al. (2013) Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr 97, 147-154.
31. Skaaby T, Husemoen LL, Thuesen BH, et al. (2014) Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer. Cancer Epidemiol Biomarkers Prev 23, 1220-1229.
32. Park SY, Murphy SP, Wilkens LR, et al. (2007) Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. Am J Epidemiol 166, 1259-1269.
33. Li H, Stampfer MJ, Hollis JB, et al. (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4, e103.
34. Albanes D, Mondul AM, Yu K, et al. (2011) Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested casecontrol study. Cancer Epidemiol Biomarkers Prev 20, 1850-1860.
35. Vieth R (2009) How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. Anticancer Res 29, 3675-3684.
36. Vernay M, Sponga M, Salavane B, et al. (2012) Statut en vitamine D de la population adulte en France: l'Etude nationale nutrition sante (ENNS 2006-2007) (Vitamin D status in the French adult population: the French Nutrition and Health Survey (ENNS, 2006-2007)). Bulletin Epidemiologique Hebdomadaire (BEH) (Bull Epidemiol Hebd) 16-17, 189-194.
37. Major JM, Graubard BI, Dodd KW, et al. (2013) Variability and reproducibility of circulating vitamin D in a nationwide U.S. population. J Clin Endocrinol Metab 98, 97-104.
38. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357, 266-281.
39. Saquib N, von MD, Garland CF, et al. (2006) Serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in men: the Rancho Bernardo study. Osteoporos Int 17, 1734-1741.
40. Fedirko V, Riboli E, Bueno-De-Mesquita HB, et al. (2011) Prediagnostic circulating parathyroid hormone concentration and colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer Epidemiol Biomarkers Prev 20, 767-778.
41. McCarty MF (2000) Parathyroid hormone may be a cancer promoter-an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Med Hypotheses 54, 475-482.
42. Ritchie CK, Thomas KG, Andrews LR, et al. (1997) Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis. Prostate 30, 183-187.
43. Bikle DD (2008) Growth hormone/insulin-like growth factor-1/PTH axis in bone. J Bone Miner Res 23, 581-583.
44. Gasperi M, Cecconi E, Grasso L, et al. (2002) GH secretion is impaired in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 87, 1961-1964.
45. Price AJ, Allen NE, Appleby PN, et al. (2012) Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev 21, 1531-1541.
46. Roddam AW, Allen NE, Appleby P, et al. (2008) Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149, 461-468.
47. Jorde R, Sundsfjord J, & Bonaa KH (2001) Determinants of serum calcium in men and women. The Tromso Study. Eur J Epidemiol 17, 1117-1123.